Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.000000
forwardPE 31.152336
debtToEquity 0.892000
earningsGrowth 0.115000
revenueGrowth 0.037000
grossMargins 0.755900
operatingMargins 0.248540
trailingEps 71.620000
forwardEps 99.280000

Ajanta Pharma Limited's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
With AJANTPHARM's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in AJANTPHARM's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Over time, AJANTPHARM's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for AJANTPHARM.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


14 sales transactions of AJANTPHARM were conducted, with market price at 2860.214285714286.Throughout the period under consideration, there were no sell transactions.AJANTPHARM's current price levels are experiencing more buying activity than selling, which may point to a favorable outlook. This trend suggests investor confidence in the stock's future, potentially indicating expectations of continued growth.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts have shown a buy bias for AJANTPHARM, marking it as a favorable investment option. This could inspire investors to see AJANTPHARM as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.